Carbapenemase-producing Enterobacteriaceae

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 1, 2015, Pages 74-84

  Doi, Yohei ^a   Paterson, David L ^b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Queensland Health   (Australia)

Author keywords

antimicrobial resistance; carbapenemases; Enterobacteriaceae; Klebsiella pneumoniae

Indexed keywords

AMIKACIN; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CARBAPENEM DERIVATIVE; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; DOXYCYCLINE; ERAVACYCLINE; FOSFOMYCIN; GENTAMICIN; PLAZOMICIN; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM DETECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGY; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); NEW DELHI PRODUCING ENTEROBACTERIACEAE; NONHUMAN; OBSERVATIONAL STUDY; OXA 48 PRODUCING KLEBSIELLA PNEUMONIAE; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; METABOLISM; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 84922169860     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1544208     Document Type: Article

References (100)

1. Rasmussen B. A.; Bush K. Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother: 1997; 41 2 223 232
2. Martínez-Martínez L.; Pascual A.; Hernández-Allés S.; et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother: 1999; 43 7 1669 1673
3. Yigit H.; Queenan A. M.; Anderson G. J.; et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother: 2001; 45 4 1151 1161
4. Bradford P. A.; Bratu S.; Urban C.; et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis: 2004; 39 1 55 60
5. Bratu S.; Landman D.; Haag R.; et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med: 2005; 165 12 1430 1435
6. Kitchel B.; Rasheed J. K.; Patel J. B.; et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother: 2009; 53 8 3365 3370
7. Gupta N.; Limbago B. M.; Patel J. B.; Kallen A. J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis: 2011; 53 1 60 67
8. Samra Z.; Ofir O.; Lishtzinsky Y.; Madar-Shapiro L.; Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents: 2007; 30 6 525 529
9. Navon-Venezia S.; Leavitt A.; Schwaber M. J.; et al. Israeli KPC Kpn Study Group. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother: 2009; 53 2 818 820
10. Schwaber M. J.; Lev B.; Israeli A.; et al. Israel Carbapenem-Resistant Enterobacteriaceae Working Group. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis: 2011; 52 7 848 855
11. Schwaber M. J.; Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis: 2014; 58 5 697 703
12. Maltezou H. C.; Giakkoupi P.; Maragos A.; et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect: 2009; 58 3 213 219
13. VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother: 2008; 61 1 59 63
14. Agodi A.; Voulgari E.; Barchitta M.; et al. Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in Italy. J Clin Microbiol: 2011; 49 11 3986 3989
15. Giani T.; Pini B.; Arena F.; et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill: 2013; 18 22
16. Munoz-Price L. S.; Poirel L.; Bonomo R. A.; et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis: 2013; 13 9 785 796
17. Woodford N.; Turton J. F.; Livermore D. M. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev: 2011; 35 5 736 755
18. Warburg G.; Hidalgo-Grass C.; Partridge S. R.; et al. A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6′)-Ib. J Antimicrob Chemother: 2012; 67 4 898 901
19. Capone A.; Giannella M.; Fortini D.; et al. SEERBIO-GRAB network. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect: 2013; 19 1 E23 E30
20. Qi Y.; Wei Z.; Ji S.; Du X.; Shen P.; Yu Y. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J Antimicrob Chemother: 2011; 66 2 307 312
21. Pereira P. S.; de Araujo C. F.; Seki L. M.; Zahner V.; Carvalho-Assef A. P.; Asensi M. D. Update of the molecular epidemiology of KPC-2-producing Klebsiella pneumoniae in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340). J Antimicrob Chemother: 2013; 68 2 312 316
22. Ruiz-Garbajosa P.; Curiao T.; Tato M.; et al. Multiclonal dispersal of KPC genes following the emergence of non-ST258 KPC-producing Klebsiella pneumoniae clones in Madrid, Spain. J Antimicrob Chemother: 2013; 68 11 2487 2492
23. O'Hara J. A.; Hu F.; Ahn C.; et al. Molecular epidemiology of KPC-producing Escherichia coli: occurrence of ST131- fimH 30 subclone harboring pKpQIL-like IncFIIk plasmid. Antimicrob Agents Chemother: 2014; 58 7 4234 4237
24. Ahn C.; Syed A.; Hu F.; O'Hara J. A.; Rivera J. I.; Doi Y. Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system. Diagn Microbiol Infect Dis: 2014; 80 2 154 158
25. Robledo I. E.; Aquino E. E.; Vázquez G. J. Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCR-based nosocomial surveillance study in Puerto Rico. Antimicrob Agents Chemother: 2011; 55 6 2968 2970
26. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother: 2009; 53 12 5046 5054
27. Castanheira M.; Deshpande L. M.; Mathai D.; Bell J. M.; Jones R. N.; Mendes R. E. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother: 2011; 55 3 1274 1278
28. Castanheira M.; Deshpande L. M.; Farrell S. E.; Shetye S.; Shah N.; Jones R. N. Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. Diagn Microbiol Infect Dis: 2013; 75 2 210 213
29. Day K. M.; Ali S.; Mirza I. A.; et al. Prevalence and molecular characterization of Enterobacteriaceae producing NDM-1 carbapenemase at a military hospital in Pakistan and evaluation of two chromogenic media. Diagn Microbiol Infect Dis: 2013; 75 2 187 191
30. Zowawi H. M.; Balkhy H. H.; Walsh T. R.; Paterson D. L. β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev: 2013; 26 3 361 380
31. Meletis G.; Oustas E.; Bagkeri M. Carbapenemase reports from the Balkans: a systematic review. Infez Med: 2014; 22 2 85 106
32. Walsh T. R.; Weeks J.; Livermore D. M.; Toleman M. A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis: 2011; 11 5 355 362
33. Savard P.; Gopinath R.; Zhu W.; et al. First NDM-positive Salmonella sp. strain identified in the United States. Antimicrob Agents Chemother: 2011; 55 12 5957 5958
34. Darley E.; Weeks J.; Jones L.; et al. NDM-1 polymicrobial infections including Vibrio cholerae. Lancet: 2012; 380 9850 1358
35. Poirel L.; Héritier C.; Tolün V.; Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother: 2004; 48 1 15 22
36. Poirel L.; Potron A.; Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother: 2012; 67 7 1597 1606
37. Mathers A. J.; Hazen K. C.; Carroll J.; et al. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the menace arrives in the new world. J Clin Microbiol: 2013; 51 2 680 683
38. Thaden J. T.; Lewis S. S.; Hazen K. C.; et al. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol: 2014; 35 8 978 983
39. Nordmann P.; Gniadkowski M.; Giske C. G.; Poirel L.; Woodford N.; Miriagou V.; European Network on Carbapenemases. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect: 2012; 18 5 432 438
40. Anderson K. F.; Lonsway D. R.; Rasheed J. K.; et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol: 2007; 45 8 2723 2725
41. Nordmann P.; Poirel L.; Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis: 2012; 18 9 1503 1507
42. Vasoo S.; Cunningham S. A.; Kohner P. C.; et al. Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing Gram-negative bacilli. J Clin Microbiol: 2013; 51 9 3097 3101
43. Doi Y.; Potoski B. A.; Adams-Haduch J. M.; Sidjabat H. E.; Pasculle A. W.; Paterson D. L. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type β-lactamase by use of a boronic acid compound. J Clin Microbiol: 2008; 46 12 4083 4086
44. Tsakris A.; Themeli-Digalaki K.; Poulou A.; et al. Comparative evaluation of combined-disk tests using different boronic acid compounds for detection of Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae clinical isolates. J Clin Microbiol: 2011; 49 8 2804 2809
45. Hattori T.; Kawamura K.; Arakawa Y. Comparison of test methods for detecting metallo-β-lactamase-producing Gram-negative bacteria. Jpn J Infect Dis: 2013; 66 6 512 518
46. Cuzon G.; Naas T.; Bogaerts P.; Glupczynski Y.; Nordmann P. Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother: 2012; 67 8 1865 1869
47. Lolans K.; Calvert K.; Won S.; Clark J.; Hayden M. K. Direct ertapenem disk screening method for identification of KPC-producing Klebsiella pneumoniae and Escherichia coli in surveillance swab specimens. J Clin Microbiol: 2010; 48 3 836 841
48. Adler A.; Navon-Venezia S.; Moran-Gilad J.; Marcos E.; Schwartz D.; Carmeli Y. Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J Clin Microbiol: 2011; 49 6 2239 2242
49. Landman D.; Salvani J. K.; Bratu S.; Quale J. Evaluation of techniques for detection of carbapenem-resistant Klebsiella pneumoniae in stool surveillance cultures. J Clin Microbiol: 2005; 43 11 5639 5641
50. NDM from surveillance samples. J Clin Microbiol: 2013; 51 11 3609 3615
51. Bergen P. J.; Landersdorfer C. B.; Zhang J.; et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis: 2012; 74 3 213 223
52. Akajagbor D. S.; Wilson S. L.; Shere-Wolfe K. D.; Dakum P.; Charurat M. E.; Gilliam B. L. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis: 2013; 57 9 1300 1303
53. Garonzik S. M.; Li J.; Thamlikitkul V.; et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother: 2011; 55 7 3284 3294
54. Florescu D. F.; Qiu F.; McCartan M. A.; Mindru C.; Fey P. D.; Kalil A. C. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis: 2012; 54 5 670 680
55. Mohamed A. F.; Karaiskos I.; Plachouras D.; et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother: 2012; 56 8 4241 4249
56. Li J.; Milne R. W.; Nation R. L.; Turnidge J. D.; Smeaton T. C.; Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother: 2004; 53 5 837 840
57. Plachouras D.; Karvanen M.; Friberg L. E.; et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother: 2009; 53 8 3430 3436
58. Imberti R.; Cusato M.; Villani P.; et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest: 2010; 138 6 1333 1339
59. Kwa A. L.; Lim T. P.; Low J. G.; et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis: 2008; 60 2 163 167
60. Mammina C.; Bonura C.; Di Bernardo F.; et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill: 2012; 17 33 20248
61. Bogdanovich T.; Adams-Haduch J. M.; Tian G. B.; et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis: 2011; 53 4 373 376
62. Mezzatesta M. L.; Gona F.; Caio C.; et al. Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect: 2011; 17 9 1444 1447
63. Al-Agamy M. H.; Shibl A. M.; Elkhizzi N. A.; Meunier D.; Turton J. F.; Livermore D. M. Persistence of Klebsiella pneumoniae clones with OXA-48 or NDM carbapenemases causing bacteraemias in a Riyadh hospital. Diagn Microbiol Infect Dis: 2013; 76 2 214 216
64. Arpin C.; Noury P.; Boraud D.; et al. NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient without history of foreign travel. Antimicrob Agents Chemother: 2012; 56 6 3432 3434
65. van Duin D.; Perez F.; Rudin S. D.; et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother: 2014; 58 7 4035 4041
66. van Duin D.; Cober E. D.; Richter S. S.; et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect: 2014; 20 12 O1117 O1120
67. Barbour A.; Schmidt S.; Ma B.; et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet: 2009; 48 9 575 584
68. Freire A. T.; Melnyk V.; Kim M. J.; et al. 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis: 2010; 68 2 140 151
69. Ramirez J.; Dartois N.; Gandjini H.; Yan J. L.; Korth-Bradley J.; McGovern P. C. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother: 2013; 57 4 1756 1762
70. Tzouvelekis L. S.; Markogiannakis A.; Psichogiou M.; Tassios P. T.; Daikos G. L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev: 2012; 25 4 682 707
71. Clancy C. J.; Chen L.; Hong J. H.; et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother: 2013; 57 11 5258 5265
72. Bulik C. C.; Nicolau D. P. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother: 2011; 55 6 3002 3004
73. Giamarellou H.; Galani L.; Baziaka F.; Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother: 2013; 57 5 2388 2390
74. Naparstek L.; Carmeli Y.; Navon-Venezia S.; Banin E. Biofilm formation and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother: 2014; 69 4 1027 1034
75. Clancy C. J.; Hao B.; Shields R. K.; et al. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob Agents Chemother: 2014; 58 6 3521 3525
76. Michail G.; Labrou M.; Pitiriga V.; et al. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother: 2013; 57 12 6028 6033
77. Kontopidou F.; Giamarellou H.; Katerelos P.; et al. Group for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care units. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect: 2014; 20 2 O117 O123
78. Livermore D. M.; Mushtaq S.; Warner M.; et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother: 2011; 66 1 48 53
79. Parker S.; Lipman J.; Koulenti D.; Dimopoulos G.; Roberts J. A. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents: 2013; 42 4 289 293
80. Dinh A.; Salomon J.; Bru J. P.; Bernard L. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis: 2012; 44 3 182 189
81. KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother: 2010; 54 1 526 529
82. Livermore D. M.; Warner M.; Mushtaq S.; Doumith M.; Zhang J.; Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents: 2011; 37 5 415 419
83. Pontikis K.; Karaiskos I.; Bastani S.; et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents: 2014; 43 1 52 59
84. Tängdén T.; Hickman R. A.; Forsberg P.; Lagerbäck P.; Giske C. G.; Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother: 2014; 58 3 1757 1762
85. Whelton A.; Nightingale S. D.; Carter G. G.; Gordon L. S.; Bryant H. H.; Walker W. G. Pharmacokinetic characteristics of doxycycline accumulation in normal and severely diseased kidneys. J Infect Dis: 1975; 132 4 467 471
86. Qureshi Z. A.; Syed A.; Clarke L. G.; Doi Y.; Shields R. K. Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria. Antimicrob Agents Chemother: 2014; 58 6 3100 3104
87. Alexander B. T.; Marschall J.; Tibbetts R. J.; Neuner E. A.; Dunne W. M. Jr, Ritchie D. J. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther: 2012; 34 6 1314 1323
88. Bratu S.; Tolaney P.; Karumudi U.; et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother: 2005; 56 1 128 132
89. Abdallah M.; Olafisoye O.; Cortes C.; Urban C.; Landman D.; Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother: 2014; [Epub ahead of print]
90. Castanheira M.; Farrell S. E.; Krause K. M.; Jones R. N.; Sader H. S. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother: 2014; 58 2 833 838
91. Wang X.; Zhang F.; Zhao C.; et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother: 2014; 58 3 1774 1778
92. Li H.; Estabrook M.; Jacoby G. A.; Nichols W. W.; Testa R. T.; Bush K. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother: 2014; [Epub ahead of print]
93. Sader H. S.; Farrell D. J.; Castanheira M.; Flamm R. K.; Jones R. N. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother: 2014; 69 10 2713 2722
94. Almaghrabi R.; Clancy C. J.; Doi Y.; et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother: 2014; 58 8 4443 4451
95. O'Hara J. A.; McGann P.; Snesrud E. C.; et al. Novel 16S rRNA methyltransferase RmtH produced by Klebsiella pneumoniae associated with war-related trauma. Antimicrob Agents Chemother: 2013; 57 5 2413 2416
96. Zarkotou O.; Pournaras S.; Tselioti P.; et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect: 2011; 17 12 1798 1803
97. Qureshi Z. A.; Paterson D. L.; Potoski B. A.; et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother: 2012; 56 4 2108 2113
98. Tumbarello M.; Viale P.; Viscoli C.; et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis: 2012; 55 7 943 950
99. Daikos G. L.; Tsaousi S.; Tzouvelekis L. S.; et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother: 2014; 58 4 2322 2328
100. Tzouvelekis L. S.; Markogiannakis A.; Piperaki E.; Souli M.; Daikos G. L. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect: 2014; 20 9 862 872